Multiple Myeloma: Future Directions in Autologous Transplantation and Novel Agents

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1 SUPPL., 2013, Pages

  Hari, Parameswaran N ^a   McCarthy, Philip L ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HUMAN; MORBIDITY; MULTIPLE MYELOMA; PATIENT SAFETY; QUALITY OF LIFE;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PROTEASOME INHIBITORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84871890286     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.11.002     Document Type: Article

References (32)

1. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
2. Turesson I., Velez R., Kristinsson S.Y., et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: A population-based study. J Clin Oncol 2010, 28:830-834.
3. Rajkumar S.V., Gahrton G., Bergsagel P.L. Approach to the treatment of multiple myeloma: A clash of philosophies. Blood 2011, 118:3205-3211.
4. Lahuerta J.J., Mateos M.V., Martinez-Lopez J., et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008, 26:5775-5782.
5. Martinez-Lopez J., Blade J., Mateos M.V., et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011, 118:529-534.
6. Hoering A., Crowley J., Shaughnessy J.D., et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009, 114:1299-1305.
7. Broglio K.R., Berry D.A. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101:1642-1649.
8. Keats J.J., Chesi M., Egan J.B., et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012, 120:1067-1076.
9. Paiva B., Gutierrez N.C., Rosinol L., et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012, 119:687-691.
10. Giralt S. Stem cell transplantation for multiple myeloma: Current and future status. Hematology 2012 Apr, 17(Suppl 1):S117-S120.
11. Boccadoro M., Cavallo F., Nagler A., et al. Melphalan/prednisone/lenalidomide (MPR) versus high dose melphalan and autologous transplantation (MEL 200) in newly diagnosed MM. J Clin Oncol 2011, 29(suppl). abstr 8020.
12. Rajkumar S.V., Jacobus S., Callander N.S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37.
13. Cohen H.J., Bartolucci A.A., Forman W.B., et al. Consolidation and maintenance therapy in multiple myeloma: Randomized comparison of a new approach to therapy after initial response to treatment. J Clin Oncol 1986, 4:888-899.
14. Stewart A.K., Richardson P.G., San-Miguel J.F. How I treat multiple myeloma in younger patients. Blood 2009, 114:5436-5443.
15. Cavo M., Pantani L., Petrucci M.T., et al. GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012, 120:9-19.
16. Usmani S.Z., Crowley J., Hoering A., et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: Are patients now being cured?. Leukemia 2012 Jun 18, [Epub ahead of print]. 10.1038/leu.2012.160.
17. Mihelic R., Kaufman J., Lonial S. Maintenance therapy in multiple myeloma. Leukemia 2007, 21:1150-1157.
18. Berenson J.R., Crowley J.J., Grogan T.M., et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002, 99:3163-3168.
19. Fritz E., Ludwig H. Interferon-alpha treatment in multiple myeloma: Meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000, 11:1427-1436.
20. Remission maintenance therapy for multiple myeloma. Arch Intern Med 1975, 135:147-152. Southwest Oncology Group.
21. Ladetto M., Pagliano G., Ferrero S., et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010, 28:2077-2084.
22. Mitsiades C.S., Davies F.E., Laubach J.P., et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol 2011, 29:1916-1923.
23. Munshi N.C., Anderson K.C., Bergsagel P.L., et al. Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700.
24. Lokhorst H.M., van der Holt B., Zweegman S., et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115:1113-1120.
25. Harousseau J.L., Attal M., Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 2010, 28:4621-4629.
26. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 2010, 376:2075-2085.
27. Rosinol L., Oriol A., Teruel A.I., et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study. Blood 2012, 120:1589-1596.
28. Sonneveld P., Schmidt-Wolf I.G., van der Holt B., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012, 30:2946-2955.
29. Moreau P., Avet-Loiseau H., Facon T., et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011, 118:5752-5758.
30. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
31. Kumar S., Flinn I., Richardson P.G., et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012, 119:4375-4382.
32. Jakubowiak A.J., Dytfeld D., Griffith K.A., et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012, 120:1801-1809.